A phase 1-2 safety and efficacy study of panzem nanocrystal colloidal dispersion administered orally in combination with rhuMAb VEGF (Bevacizumab) in patients with locally advanced or metastatic carcinoid tumors

Trial Profile

A phase 1-2 safety and efficacy study of panzem nanocrystal colloidal dispersion administered orally in combination with rhuMAb VEGF (Bevacizumab) in patients with locally advanced or metastatic carcinoid tumors

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2014

At a glance

  • Drugs 2-methoxyestradiol (Primary) ; Bevacizumab
  • Indications Carcinoid tumour
  • Focus Therapeutic Use
  • Sponsors CASI Pharmaceuticals; EntreMed
  • Most Recent Events

    • 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 28 Jan 2008 Interim results were reported in an EntreMed media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top